{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:12:08Z","timestamp":1774732328099,"version":"3.50.1"},"reference-count":128,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clindermatol.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:20:44Z","timestamp":1742242844000},"page":"669-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prurigo nodularis in 2025: Current and emerging treatments"],"prefix":"10.1016","volume":"43","author":[{"given":"Sarah G.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2025.03.013_bib0001","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jdv.19936","article-title":"Prurigo nodularis: A \u201cCinderella\u201d disease with significant burden and a bright future","volume":"38","author":"Yosipovitch","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0002","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1159\/000523700","article-title":"Non-atopic chronic nodular prurigo (prurigo nodularis Hyde): a systematic review of best-evidenced treatment options","volume":"238","author":"Fr\u00f8lunde","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0003","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40257-021-00629-0","article-title":"Appraisal of proactive topical therapy in atopic dermatitis: pros and cons","volume":"22","author":"Fr\u00f8lunde","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0004","article-title":"Topical corticosteroids","author":"Gabros","year":"2022","journal-title":"StatPearls [Internet]"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/09546630903386606","article-title":"An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis","volume":"21","author":"Saraceno","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1684\/ejd.2017.3164","article-title":"The use of biodegradable microneedle patches to increase penetration of topical steroid for prurigo nodularis","volume":"28","author":"Shin","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0007","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/0378-6323.178903","article-title":"Topical corticosteroids in dermatology","volume":"82","author":"Mehta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0008","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/tcrm.2006.2.2.213","article-title":"Treatment of pruritic diseases with topical calcineurin inhibitors","volume":"2","author":"St\u00e4nder","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000355671","article-title":"Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial","volume":"227","author":"Siepmann","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0011","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1067\/mjd.2001.110059","article-title":"Treatment of prurigo nodularis with topical capsaicin","volume":"44","author":"St\u00e4nder","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0625.2007.00664.x","article-title":"Neurophysiological and neurochemical basis of modern pruritus treatment","volume":"17","author":"St\u00e4nder","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(25)06664-5","article-title":"Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons","volume":"43","author":"Holzer","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0014","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1476-5381.1967.tb01984.x","article-title":"Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin","volume":"31","author":"Jancs\u00f3","year":"1967","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jpain.2005.04.008","article-title":"Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study","volume":"6","author":"Lynch","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jaad.2013.03.013","article-title":"Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritus: a retrospective pilot study","volume":"69","author":"Poterucha","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0017","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0018","unstructured":"Press Release: Dupixent\u00ae (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis. September 28, 2022. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-09-28-22-05-26-2524764. Accessed October 30, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0020","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0021","article-title":"Dupilumab for the treatment of prurigo nodularis: A systematic review","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0022","unstructured":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME). ClinicalTrials.gov NCT04183335. Updated December 12, 2022. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04183335. Accessed August 30, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0023","unstructured":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2). ClinicalTrials.gov NCT04202679. Updated December 21, 2022. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04202679. Accessed September 3, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0024","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.abd.2022.09.008","article-title":"A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis","volume":"98","author":"Zhang","year":"2023","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0025","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/jcm13030878","article-title":"Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks","volume":"13","author":"Paganini","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0026","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/jdv.15957","article-title":"Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients","volume":"34","author":"Calugareanu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0027","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/jdv.18221","article-title":"Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors","volume":"36","author":"Gael","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0028","unstructured":"US Food and Drug Administration. FDA approves first treatment for prurigo nodularis Available at:. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-prurigo-nodularis, 2022. Accessed October 15, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0090","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/jdv.18377","article-title":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances","volume":"36","author":"St\u00e4nder","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.clindermatol.2025.03.013_bib0092","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0094","unstructured":"An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis. ClinicalTrials.gov NCT04501666. Updated June 28, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04501666. Accessed July 10, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0095","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0100","unstructured":"Galderma. Galderma announces regulatory filing acceptance for its investigational treatment in prurigo nodularis and atopic dermatitis in the U.S. and EU. [press release]. February 14, 2024. Available at: https:\/\/www.galderma.com\/news\/galderma-announces-regulatory-filing-acceptance-nemolizumab-prurigo-nodularis-and-atopic. Accessed March 10, 2024."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib128","unstructured":"Galderma. Galderma receives U.S. FDA approval for Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. [press release]. August 13, 2024. Available at https:\/\/www.galderma.com\/news\/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo. Accessed April 9, 2025."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0093","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0091","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","article-title":"Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis","volume":"113","author":"Serra-Baldrich","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0096","series-title":"American Academy of Dermatology 2023 Annual Meeting","article-title":"Nemolizumab monotherapy improves itch, skin lesions, and sleep disturbance in patients with prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)","author":"Kwatra","year":"2023"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0097","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/1744666X.2024.2306225","article-title":"A critical evaluation of nemolizumab for prurigo nodularis","volume":"20","author":"Brooks","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.clindermatol.2025.03.013_bib129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and Safety of Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial","volume":"161","author":"Stander","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0099","series-title":"American Academy of Dermatology 2023 Annual Meeting","article-title":"Nemolizumab long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: an interim analysis","author":"Kwatra","year":"2023"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib130","first-page":"25","article-title":"Durability of response to nemolizumab in patients with moderate-to-severe prurigo nodularis: Results from a randomised placebo-controlled withdrawal Phase 3b study. 2024","author":"Legat","year":"2024","journal-title":"Abstract presented at: European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: Quintiles Prize Lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0031","series-title":"StatPearls [Internet]","article-title":"Corticosteroids","author":"Hodgens","year":"2023"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0032","series-title":"StatPearls [Internet]","article-title":"Corticosteroid adverse effects","author":"Yasir","year":"2023"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0033","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0034","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1529-8019.2007.00135.x","article-title":"Methotrexate in dermatology","volume":"20","author":"Bangert","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/ced.12365","article-title":"Prurigo nodularis: retrospective study of 13 cases managed with methotrexate","volume":"39","author":"Spring","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0036","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1610-0387.2008.06745.x","article-title":"Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series","volume":"6","author":"Siepmann","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0037","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2018.02.024","article-title":"Rapid improvement of prurigo nodularis with cyclosporine treatment","volume":"78","author":"Wiznia","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0038","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/archdermatol.2011.79","article-title":"Off-label use of azathioprine in dermatology: a systematic review","volume":"147","author":"Schram","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0039","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.abd.2020.05.003","article-title":"Azathioprine: its uses in dermatology","volume":"95","author":"Chavez-Alvarez","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/14622416.9.3.303","article-title":"Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study","volume":"9","author":"Cooper","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0041","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115706","article-title":"Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation","volume":"168","author":"D\u00edaz-Villamar\u00edn","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0043","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-199912000-00012","article-title":"Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals","volume":"9","author":"McLeod","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0044","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s11095-023-03558-1","article-title":"Genome-wide association study for the genetic determinants of thiopurine methyltransferase protein expression in human livers and racial differences","volume":"40","author":"Smith","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0045","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.7326\/M21-4675","article-title":"Race, genotype, and azathioprine discontinuation: a cohort study","volume":"175","author":"Dickson","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0046","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clindermatol.2017.01.008","article-title":"Psychiatric disorders and pruritus","volume":"35","author":"Lee","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0047","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1468-3083.2001.00278.x","article-title":"The use of antidepressant drugs in dermatology","volume":"15","author":"Gupta","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0048","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.62.2.212","article-title":"Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch","volume":"62","author":"Ikoma","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0049","doi-asserted-by":"crossref","DOI":"10.5070\/D3243038611","article-title":"Thalidomide for the treatment of chronic refractory prurigo nodularis","volume":"24","author":"Aguh","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0051","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0052","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","article-title":"Thalidomide: current and potential clinical applications","volume":"108","author":"Calabrese","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0053","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis Hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0054","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13555-016-0122-9","article-title":"A review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis","volume":"6","author":"Lim","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12451","article-title":"Treatment of prurigo nodularis with lenalidomide","volume":"30","author":"Ossorio-Garc\u00eda","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0057","article-title":"Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis","volume":"11","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0058","article-title":"The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: a meta-analysis","volume":"102","author":"Liu","year":"2023","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"St\u00e4nder","year":"2010","journal-title":"PLOS One"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2340\/00015555-3120","article-title":"Aprepitant in anti-histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II trial (APREPRU)","volume":"99","author":"Tsianakas","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0061","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3347","article-title":"A new generation of treatments for itch","volume":"100","author":"Fowler","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0062","unstructured":"GlobeNewswire. Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis Conference call today at 8.30am EDT [press release]. https:\/\/www.globenewswire.com\/news-release\/2020\/04\/06\/2012003\/0\/en\/Menlo-Therapeutics-Announces-Results-from-Two-Phase-3-Clinical-Trials-of-Serlopitant-for-the-Treatment-of-Pruritus-Associated-with-Prurigo-Nodularis.html, 2020. Accessed April 10, 2024."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0063","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0064","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits","volume":"31","author":"Kim","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0066","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","article-title":"Antipruritic treatment with systemic \u03bc-opioid receptor antagonists: a review","volume":"63","author":"Phan","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0067","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus","volume":"28","author":"Lee","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0068","first-page":"533","article-title":"Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases","volume":"41","author":"Metze","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0069","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0070","first-page":"931","article-title":"The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers","volume":"82","author":"Zacny","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0077","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1346-8138.2007.00360.x","article-title":"Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo","volume":"34","author":"Tamagawa-Mineoka","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0078","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ad.2020.11.007","article-title":"Phototherapy for prurigo nodularis: our experience and a review of the literature","volume":"112","author":"Arrieta","year":"2021","journal-title":"Actas Dermosifiliogr (Engl)"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0079","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-4362.1990.tb03833.x","article-title":"UV treatment of generalized prurigo nodularis","volume":"29","author":"Hann","year":"1990","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0080","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/pho.2008.2317","article-title":"Different applications of monochromatic excimer light in skin diseases","volume":"27","author":"Nistic\u00f2","year":"2009","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0081","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0781.2008.00318.x","article-title":"Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis","volume":"24","author":"Saraceno","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0082","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1468-3083.2010.03865.x","article-title":"UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis","volume":"25","author":"Hammes","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0083","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2230.2009.03705.x","article-title":"Phototherapy of generalized prurigo nodularis","volume":"35","author":"Bruni","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0084","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/archderm.1984.01650480060020","article-title":"Cryotherapy improves prurigo nodularis","volume":"120","author":"Waldinger","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5114\/pdia.2015.48048","article-title":"Clinical practice trends in cryosurgery: a retrospective study of cutaneous lesions","volume":"32","author":"Afsar","year":"2015","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0086","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14855","article-title":"Prurigo nodularis comparative treatment outcome in patients attending a tertiary hospital in northern Tanzania","volume":"34","author":"Mayala","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0087","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1524-4725.1983.tb01040.x","article-title":"Treatment of prurigo nodularis: use of cryosurgery and intralesional steroids plus lidocaine","volume":"9","author":"Stoll","year":"1983","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0088","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0089","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0103","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3505","article-title":"Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716","volume":"100","author":"Richards","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0104","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: Part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2340\/00015555-3086","article-title":"Antipruritic effects of Janus kinase inhibitor tofacitinib in a mouse model of psoriasis","volume":"99","author":"Hashimoto","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0106","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/derm.2022.0065","article-title":"Failure of dupilimab with severe prurigo nodularis that responded well to abrocitinib","volume":"34","author":"Vander Does","year":"2023","journal-title":"Dermatitis"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0107","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1111\/ijd.16568","article-title":"Successful treatment of prurigo nodularis with tofacitinib: the experience from a single center","volume":"62","author":"Liu","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0108","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/ced.14320","article-title":"Successful treatment of recalcitrant nodular prurigo with tofacitinib","volume":"45","author":"Molloy","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/CCID.S354025","article-title":"Tofacitinib for prurigo nodularis: a case report","volume":"15","author":"Peng","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0112","first-page":"19","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0113","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","article-title":"Safety of Janus kinase inhibitors in older patients: a focus on the thromboembolic risk","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0115","unstructured":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN1). ClinicalTrials.gov NCT05755438. Last Updated August 21 https:\/\/clinicaltrials.gov\/study\/NCT05755438, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0116","unstructured":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2). ClinicalTrials.gov NCT05764161. Last Updated August 21 https:\/\/clinicaltrials.gov\/study\/NCT05764161, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib131","series-title":"Vehicle-Controlled Study (TRuE-PN1). Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting","first-page":"7","article-title":"Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Results From a Phase 3, Randomized","author":"Kwatra","year":"2025"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib132","unstructured":"Incyte. Incyte announces results of phase 3 clinical trials evaluating ruxolitinib cream 1.5% (opzelura) in patients with prurigo nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting. Business Wire. March 8, 2025. Accessed April 10, 2025. https:\/\/www.businesswire.com\/news\/home\/20250308179919\/en\/Incyte-Announces-Results-of-Phase-3-Clinical-Trials-Evaluating-Ruxolitinib-Cream-1.5-Opzelura%C2%AE-in-Patients-with-Prurigo-Nodularis-PN-at-2025-American-Academy-of-Dermatology-Annual-Meeting."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0118","series-title":"American Academy of Dermatology 2024 Annual Meeting","article-title":"Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: results from a randomized d-b, placebo-controlled phase 2 study","author":"Martin","year":"2024"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib135","first-page":"25","article-title":"Efficacy and Safety of oral povorcitinib in patients with prurigo nodularis: 40-week results from a randomized, double-blind, placebo-controlled phase 2 study. Presented at: 33rd European Academy of Dermatology and Venereology Congress","author":"Kwatra","year":"2024","journal-title":"September"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0119","unstructured":"Efficacy of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus ClinicalTrials.gov NCT05038982. Last updated July 3. https:\/\/clinicaltrials.gov\/study\/NCT05038982, 2023. Accessed November 29, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0120","series-title":"European Academy of Dermatology and Venereology Congress 2023","article-title":"Efficacy, safety, and mechanism of action of abrocitinib in the treatment of prurigo nodularis and chronic pruritus of unknown origin","author":"Kwatra","year":"2023"},{"issue":"7","key":"10.1016\/j.clindermatol.2025.03.013_bib133","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and Safety of Abrocinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0121","doi-asserted-by":"crossref","first-page":"e8606","DOI":"10.1002\/ccr3.8606","article-title":"Successful treatment of refractory prurigo nodularis with abrocitinib","volume":"12","author":"Sun","year":"2024","journal-title":"Clin Case Rep"},{"issue":"5","key":"10.1016\/j.clindermatol.2025.03.013_bib0122","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.anai.2018.09.063","article-title":"Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2b randomized, placebo-controlled trial","volume":"121","author":"Beck","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.clindermatol.2025.03.013_bib134","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4168\/aair.2024.16.5.546","article-title":"Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study","volume":"16","author":"Lee","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jdcr.2023.01.037","article-title":"Upadacitinib for prurigo nodularis: a case report","volume":"48","author":"Muntaner-Virgili","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0124","unstructured":"Celldex Therapeutics, Inc. Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis [press release]. https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-announces-first-patient-dosed-phase-1-study-cdx-0159, December 8, 2021. Accessed November 18, 2023."},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S316602","article-title":"Immunotargets and therapy for prurigo nodularis","volume":"11","author":"Labib","year":"2022","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100254","article-title":"Meeting report: highlights of 12th World Congress of Itch","volume":"4","author":"Brooks","year":"2024","journal-title":"JID Innov"},{"key":"10.1016\/j.clindermatol.2025.03.013_bib0127","unstructured":"Celldex Therapeutics, Inc. Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg\/kg Barzolvolimab [press release]. https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-therapeutics-presents-positive-data-prurigo-nodularis, November 5, 2023. Accessed Nov 18, 2023."},{"issue":"3","key":"10.1016\/j.clindermatol.2025.03.013_bib136","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40257-024-00850-7","article-title":"OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.clindermatol.2025.03.013_bib137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/1750743X.2025.2464528","article-title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","volume":"17","author":"Guttman-Yassky","year":"2025","journal-title":"Immunotherapy"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T02:23:38Z","timestamp":1762395818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X25000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0738081X25000963"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.03.013","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prurigo nodularis in 2025: Current and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}